ESTRO 37 Abstract book

S832

ESTRO 37

Factors taken into consideration in deciding whether to offer radiotherapy included response to prior treatments, resectability of disease, performance status, and limitations of other treatment. Results All patients underwent either upfront or delayed surgical resection of the primary tumor, bilateral salpingo- oophorectomy, total abdominal hysterectomy, and selective biopsies and resections of lymph nodes, omentum, and other suspicious findings. All patients received minimum two chemotherapy courses before radiotherapy. Radiotherapy doses ranged between 40 and 50 Gy. All patients received platinum based chemotherapy as first line of systemic treatment. Progression-free survival (PFS) rates after radiotherapy was 29 months; 95% confidence interval (CI) ( 21.4, 38). Twenty patients ( 37%) still alive. Conclusion Radiotherapy can yield excellent local control and disease-free intervals in patients who progressed after few lines of systemic treatment . Radiotherapy could be considered l in the management of locoregionally- recurrent ovarian cancer. EP-1536 Quality of Life in cervical cancer patients: A weak relationship exists between PRO and PhRO. R. Ordoñez Marmolejo 1 1 virgen De La Victoria, Oncologia Radioterapica, Málaga, Spain Purpose or Objective To analyze Health-Related Quality of Life (HR-QoL) in cervical cancer patients treated with a curative intent and it relationship with late morbidity and clinical factors. Material and Methods QoL was assessed at a median follow-up of 43 months in 166 patients using European Organization for Research and Treatment of Cancer (EORTC)-C30 (core module), EORTC-Cx24 (cervical module), and Female Sexual Function Index (FSFI, a dimension specific questionnaire on sexual function). A multivariable analysis was performed to clarify prognostic factors that correlate with QoL and late morbidity. Results Patients reported a good or a very good general QoL (scores 72,2± 25,8). Emotional functioning was the most impaired scale (68,2±29,4). The population is sexually low active (38% sexually active) with a score compatible with sexual dysfunction on the FSFI scale (12.5 ± 9.9). Patients engaged in sexual activity showed a higher general QoL (B 12,7), physical functioning (B 11,1) and role functioning (B 14,5), expressed lower symptom experience (B -11,1) and, as expected, it had a positive impact in all the IFSF sub-scales (desire: B 0,9; arousal: B 3,8; lubrication: B 3,6; orgasm: B 4,2; satisfaction: B 1,2; and pain: B 3,9). It was only found a statistically significant relationship between QLQ-C30 general QoL (p=0,006) and QLQ-Cx24 symptom experience (p=0,005) in PRO and the Physician Reported Outcomes (PhRO), measured as maximum late toxicity (worst skin, rectal, bowel, urinary and sexual toxicity during follow up). No association was found between maximum sexual late toxicity and sexual/vaginal functioning, sexual worry, sexual activity and sexual enjoiment (QLQ-Cx24) nor IFSF scales. Conclusion

A weak relationship exists between Patient Reported Outcomes and Physician Reported Outcomes.

EP-1537 Omission Of Prophylactic Inguinal Irradiation In Stage Iiia Cervical Cancer – Study Of 41 Patients M.A. Dadzie 1 , V. Vanderpuye 1 , F. Asamoah 1 , J. Yarney 1 , N.A. Aryeetey 1 1 Korlebu Teaching Hospital, National Centre for Radiotherapy and Nuclear Medicine, ACCRA, Ghana Purpose or Objective Prophylactic inguinal lymph node irradiation is the current standard of management for stage IIIA cervical cancer to reduce inguinal lymph node recurrence. We present the pattern of recurrence in 41 women with stage IIIA cervical cancer treated with concurrent chemo- radiation with Cobalt -60 teletherapy and brachytherapy without prophylactic inguinal lymph node irradiation. Material and Methods A retrospective study of post treatment recurrence patterns in Stage IIIA cervical cancer cases managed in Accra, Ghana over a 5 year period (2006-2011). Results Seventy two cases of stage IIIA cervical cancer were seen between January 2006 and December 2011. None had clinically positive inguinal lymphadenopathy. Average age was 58years. Majority (95%) had squamous cell carcinoma. 41 (70%)completed concurrent chemo radiation with weekly cisplatin to an average dose of 80Gy to point A. Treatment comprised of external beam radiotherapy with 2-D parallel opposed anterior-posterior fields to pelvis including whole vagina using Cobalt-60 teletherapy and low-dose rate brachytherapy with tandem and ovoids. None received complete prophylactic inguinal lymph node irradiation. After a median follow up of 48months, 8 (19.5%) recurred including 5 (62.5%) distant recurrences and 3 (37.5%) local recurrences. None developed inguinal lymph node recurrence Conclusion Prophylactic complete inguinal lymph node irradiation in cervical cancer patients with lower vaginal involvement (Stage IIIA) may not be indicated in absence of clinically positive inguinal lymphadenopathy. Further research is warranted. EP-1538 Combining EBRT and HDR-BT in high-risk prostate cancer: an effective and safe experience D. Candini 1 , F. Lopez-Campos 1 , T. Muñoz 1 , M. Martín 1 , C. Vallejo 1 , A. Hervás 1 1 Hospital Ramon y Cajal, Radiation Oncology, Madrid, Spain Purpose or Objective To evaluate acute and sub-acute genitourinary (GU) and gastrointestinal (GI) toxicity after external beam radiotherapy (EBRT) and a boost of High-Dose-Rate Brachytherapy (HDR-BT) in high-risk prostate cancer patients. Material and Methods Patients with prostate cancer, histologically confirmed, were enrolled. Selection criteria included: M0; high-risk features, according to NCCN and EAU guidelines; no trans-urethral resection of the prostate in the previous twelve months; no anesthesiological contraindications. All patients received hypofractionated and image-guided Electronic Poster: Clinical track: Prostate